Trial Profile
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Sarcoma vaccine MabVax/Memorial Sloan Kettering Cancer Center (Primary) ; OPT 821
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma; Synovial sarcoma
- Focus Proof of concept; Therapeutic Use
- Sponsors MabVax Therapeutics
- 07 Oct 2022 Results assessing the efficacy of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery published in the European Journal of Cancer.
- 14 Apr 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Jun 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov record.